Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage (NCT04153253) | Clinical Trial Compass
CompletedPhase 4
Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage
Kuwait34 participantsStarted 2018-03-07
Plain-language summary
Prospective study comparing efficacy and safety of intravitreal aflibercept injection and panretinal photocoagulation to early vitrectomy for patients with diabetic vitreous hemorrhage.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age above 18 years.
* Any sex.
* Type Ι or ΙΙ DM,
* recent diabetic VH which is causing vision impairment, precluding complete PRP and needing treatment.
* BCVA is less than 20/70 (log MAR BCVA 0.6) and better than 20/1000 (log MAR BCVA 1.7).
Exclusion Criteria:
* Tractional retinal detachment.
* Previous PRP.
* History of anti VEGF therapy within the past two months.
* Neovascular glaucoma
* Subhyaloid hemorrhage.
* Vitreomacular traction.
* Diabetic macular edema .
* Patients with systemic contraindications for anti VEGF or unstable medical conditions as uncontrolled hypertension (persistently above 180/110 mmhg) or recent thromboembolic event within the past six months.
What they're measuring
1
Mean best corrected visual acuity(BCVA) change in both groups.